Short Communication

Human myeloid-derived suppressor cell expansion during sepsis is revealed by unsupervised clustering of flow cytometric data

Marco De Zuani¹, Marcela Hortová-Kohoutková¹, Ivana Andrejčinová¹,², Veronika Tomášková¹,³, Vladimír Šrámek³, Martin Helán¹,³ and Jan Frič¹,⁴

¹ International Clinical Research Center, St. Anne’s University Hospital Brno, Brno, Czech Republic
² Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
³ Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
⁴ Department of Modern Immunotherapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Myeloid-derived suppressor cells (MDSCs) are important regulators of immune processes during sepsis in mice. However, confirming these observations in humans has been challenging due to the lack of defined preparation protocols and phenotyping schemes for MDSC subsets. Thus, it remains unclear how MDSCs are involved in acute sepsis and whether they have a role in the long-term complications seen in survivors. Here, we combined comprehensive flow cytometry phenotyping with unsupervised clustering using self-organizing maps to identify the three recently defined human MDSC subsets in blood from severe sepsis patients, long-term sepsis survivors, and age-matched controls. We demonstrated the expansion of monocytic M-MDSCs and polymorphonuclear PMN-MDSCs, but not early-stage (e)-MDSCs during acute sepsis. High levels of PMN-MDSCs were also present in long-term survivors many months after discharge, suggesting a possible role in sepsis-related complications. Altogether, by employing unsupervised clustering of flow cytometric data we have confirmed the likely involvement of human MDSC subsets in acute sepsis, and revealed their expansion in sepsis survivors at late time points. The application of this strategy in future studies and in the clinical/diagnostic context would enable rapid progress toward a full understanding of the roles of MDSC in sepsis and other inflammatory conditions.

Keywords: Flow cytometry · Multidimensional clustering · Myeloid-derived suppressor cells · Sepsis · Septic shock

Additional supporting information may be found online in the Supporting Information section at the end of the article.
Introduction

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with strong immunosuppressive activity, especially on T cells and NK cells [1]. MDSCs are present at low frequencies in healthy donors (HD), but rapidly expand in pathological conditions including cancer, autoimmunity, and bacterial, fungal, and viral infections [1–5]. Although most of the studies proved that MDSCs play a pathologic role in these conditions by suppressing the protective immune response, few other reported that MDSC expansion might actually be beneficial, restraining potentially damaging inflammation [1, 6–8].

The MDSC population has classically been divided into two major subsets based on differences in morphology and phenotype: polymorphonuclear (PMN)-MDSCs and monocytic (M)-MDSCs. While murine MDSC phenotypes are widely accepted, studies of human MDSCs have used different markers to identify them and various methods of sample preparation [9, 10], leading to a lack of consensus. The most recent classification of human MDSCs identified three major subsets: monocytic myeloid-derived suppressor cells (M-MDSCs) (CD11b+, CD14+, HLA-DR−/lo, CD15−), polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) (CD15+, CD66b+, CD11b+, CD14+), and early-stage (e)-MDSCs (CD3/14/15/19/56−, HLA-DR−, CD33+, CD11b+) comprising more immature myeloid progenitors [10]. How these subsets respond during the course of infection and inflammation, both in the acute phase of disease and during its resolution, is currently unknown.

Sepsis is a life-threatening syndrome which is mainly caused by a dysregulated host response to pathogen infection, and affects approximately 50 million people worldwide every year [11]. Mouse models of acute sepsis show an accumulation of MDSCs, especially in the secondary lymphoid organs [12, 13]. However, the few studies that have investigated MDSCs’ role in acute human sepsis have used various sample preparation procedures and minimal flow cytometry panels to distinguish the different subsets [14], leaving the overall picture unclear. Some studies have indicated that MDSC frequency positively correlates with poor outcomes in acute sepsis patients, and may remain elevated for several weeks during recovery [15, 16]; however, a comprehensive analysis of MDSC subsets in sepsis patients and in long-term survivors, who frequently exhibit chronic immunosuppression, is lacking.

Here, we used an advanced flow cytometric panel built on the most recent MDSC definition together with unsupervised clustering techniques to investigate the frequencies of the three main MDSCs subsets during acute sepsis, in sepsis survivors, and in HD.

Results and discussion

To investigate the changes in MDSC subset abundance during sepsis, we enrolled 12 patients affected by acute septic shock, 6 long-term sepsis survivors, and 7 age-matched HD (Table 1). We labelled peripheral blood mononuclear cells (PBMCs) to identify M-MDSCs (CD11b+, CD14+, HLA-DR−/lo, CD15−), PMN-MDSCs (CD15+, CD66b+, CD11b+, CD14+), and e-MDSCs (CD3/14/15/19/56−, HLA-DR−, CD33+, CD11b+) (Fig. 1A, Supporting information Fig. S1). When we gated these populations manually, we saw significantly higher frequencies of both M-MDSC and PMN-MDSC, but not e-MDSCs, in septic patients at both time points (TP1, TP2), compared to HD (Fig. 1B). These results are in concert with other studies showing the accumulation of MDSCs in sepsis patients [6, 16, 17]. Interestingly, we found that PMN-MDSCs, but not M- and e-MDSCs, were also significantly more frequent in the blood of recovered patients than in HD, with their frequency showing a linear decrease with time (Fig. 1B and C, Supporting information Fig. S2). Typically, recovered patients exhibit persistent low-grade inflammation and immunosuppression which results in poor functional independence, increased susceptibility to secondary infection and reduced survival [15, 18]. These results call for investigation of the potential role of MDSCs subsets in sepsis survivors.

To further confirm the expansion of these MDSC subsets, we applied FlowSOM, an unsupervised multidimensional clustering of flow data based on self-organizing maps and minimum spanning tree algorithms [19]. The analysis identified two M-MDSC metaclusters and one PMN-MDSC metacluster (Fig. 1D, Supporting information Fig. S3A), all consistently expressing MDSC markers (Fig. 1E, Supporting information Fig. S3B, Table S1). The event count in each metacluster confirmed the increased frequencies of both PMN-MDSCs and M-MDSCs during sepsis (Fig. 1F), as seen with manual gating. Contrarily to the results obtained through manual gating, the number of canonical CD14+, HLA-DR+ monocytes proved to be similar between the four groups (Supporting information Fig. S3C and 3D). Furthermore, we detected an unconventional subset (CD66b+, CD15+, CD14+, HLA-DR−, CD33+, CD11b+) which was significantly increased in the earliest time point of sepsis but returned to physiological levels in sepsis survivors (Fig. 1E “Unknown_1,” Supporting information Fig. S4A and 4B). Manual gating of this population confirmed its expansion at the earliest time point of sepsis, compared to HD (Supporting information Fig. S4C). A similar subset (CD14+, CD15+, CD11b+, CD33+, HLA-DR−, Lin−) was described to be expanded in nonsmall lung cancer patients and to correlate with reduced overall and progression-free survival [20]. Moreover, a novel population of PMN-neutrophils expressing high levels of CD14 and characterized by a strong immunosuppressive phenotype was recently described in the spleen of tumor-bearing mice [21].

Taken together, we demonstrate that both M-MDSCs and PMN-MDSCs but not e-MDSCs are present at high levels in patients with early-stage sepsis. Similarly, a CD14+ CD15+ CD66b+ HLA-DR+ unconventional subset was expanded at the earliest time point of sepsis. Although other studies in sepsis patients have correlated the expansion of MDSCs with higher mortality, we did not find this to be the case at the time points measured here (Fig. 1G); thus, the dynamic changes in MDSC abundance throughout the clinical course of sepsis, and their possible association with severity of the condition, require further investigation.

© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH www.eji-journal.eu
### Table 1. Cohort characteristics

| Cohort              | N     | Sex     | Age, mean (range) | Comorbidities, mean | BMI [kg/m²], mean | Mortality | Causative agent | TP1 SOFA, mean | CRP [mg/L], mean | Leucocyte count [10⁹/L], mean | Horowitz index, mean | Noradrenalin dose [μg/kg/min], mean | TP2 SOFA, mean | CRP [mg/L], mean | Leucocyte count [10⁹/L], mean | Horowitz index, mean | Noradrenalin dose [μg/kg/min], mean | Follow-up       |
|---------------------|-------|---------|-------------------|---------------------|-------------------|-----------|----------------|----------------|----------------|-----------------|--------------------------|----------------|----------------|-----------------|--------------------------|----------------|---------------------|
| Study cohort        | 12    | Female  | 6 (50%)           |                     | 27.24            |           |                | 13.3          | 240.41         | 22.23           | 204.84                   | 0.382                | 5.9                | 81.88           | 16.26                    | 295.65                   | 0.01               |                |
| Sex                 |       | Female  | 6 (50%)           |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Age, mean (range)   |       | Male    |                   |                     | 64.75 (28-77)     |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Comorbidities, mean |       |         |                   |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Hypertension, n     |       |         | 7 (58.3%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Peripheral artery disease, n |       |       | 4 (33.3%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Asthma, n           |       |         | 3 (25%)           |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Coronary heart disease, n |       |       | 4 (33.3%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| BMI [kg/m²], mean   |       |         |                   |                     | 3.25             |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Mortality           |       |         | 7 (58.3%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Causative agent     |       |         |                   |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Soft tissue infection, n |       |       | 1 (8.3%)          |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Urosepsis, n        |       |         | 5 (41.7%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Mediastinitis/empyema, n |       |       | 2 (16.7%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Pneumonia, n        |       |         | 2 (16.7%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| Unknown, n          |       |         | 2 (16.7%)         |                     |                   |           |                |               |                |                 |                          |                |                   |                 |                          |                |                   |                |
| TP1                 |       |         |                   |                     | 13.3             |           |                |               | 240.41         | 22.23           | 204.84                   | 0.382                | 5.9                | 81.88           | 16.26                    | 295.65                   | 0.01               |                |
| CRP [mg/L], mean    |       |         |                   |                     | 28.78            |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| TP2                 |       |         |                   |                     | 10.00            |           |                |               | 386.78         | 8.767           | 218.04                   | 0.09                |                   |                 |                          |                |                   |                |
| CRP [mg/L], mean    |       |         |                   |                     | 10.00            |           |                |               | 386.78         | 8.767           | 218.04                   | 0.09                |                   |                 |                          |                |                   |                |
| Leucocyte count [10⁹/L], mean |       |       |                   |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Horowitz index, mean |       |         |                   |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Noradrenalin dose [μg/kg/min], mean |       |       |                   |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Causative agent     |       |         |                   |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Abdominal infection, n |       |       | 2 (33.3%)         |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Pneumonia, n        |       |         | 1 (16.7%)         |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Mediastinitis/empyema, n |       |       | 2 (33.3%)         |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Combined, n         |       |         | 1 (16.7%)         |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Follow-up           |       |         |                   |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |
| Leucocyte count [10⁹/L], mean |       |       | 2.75              |                     |                 |           |                |               |                 |                 |                          |                |                   |                 |                          |                |                   |                |

BMI, body mass index; CRP, C-reactive protein; Horowitz index (PaO₂/FiO₂), lung function index defined as the ratio of partial pressure of oxygen in arterial blood (PaO₂) to the inspiratory fraction of oxygen (FiO₂); SOFA, sequential organ failure assessment score.
Figure 1. MDSCs are expanded during sepsis. (A) Representative gating strategy used to identify MDSCs. M-MDSCs are defined as live, CD11b+, CD15−, CD14+, HLA-DR−; PMN-MDSCs are defined as live, CD15+, CD14−, CD11b+, SSCint; e-MDSCs are defined as CD3−, CD14−, CD15−, CD19−, CD56−, HLA-DR−, CD33+, CD11b+.(B) Boxplots (Tukey) representing the frequency of M-MDSCs, PMN-MDSCs, and e-MDSCs at different time points in acute sepsis patients (TP1, TP2) in sepsis survivors (POST), and in healthy donors (HD). Pairwise comparisons were performed using Dunn’s test with multiple comparison correction. Asterisks indicate the level of significance: *p ≤ 0.05, **p ≤ 0.005, ***p < 0.001. TP1, N = 12; TP2, N = 10; POST, N = 6; HD, N = 7. (C) Linear regression of the frequency of PMN-MDSCs against the number of days from initial ICU admission in survivors. Grey area indicates 95% confidence interval. The red dashed line indicates the average PMN-MDSC frequency in healthy donors (HD). p value indicates the F-test result testing the null hypothesis of a zero slope. (D) Minimum spanning tree representation of the self-organizing map built on the complete dataset. The height of the star plots in each node represents the mean fluorescence intensity of each marker used for the clustering. The background color of each node identifies the nine metaclusters. (E) Heatmap showing the mean fluorescence intensity of the expression of the different markers in each metacluster. (F) Boxplots (Tukey) representing the normalized number of cells at different time points and in healthy donors. Pairwise comparisons were performed using Dunn’s test with Holm’s correction for multiple comparisons. Asterisks indicate the level of significance: *p ≤ 0.05, **p ≤ 0.005, ***p < 0.001. TP1, N = 12; TP2, N = 10; POST, N = 6; HD, N = 7. (G) Boxplots (Tukey) of MDSC subset frequencies at different time points (TP1, TP2) in patients that survived or succumbed to septic shock. Pairwise comparisons were performed using a Mann-Whitney U test. TP1, survivors, N = 5; TP1, nonsurvivors, N = 7; TP2, survivors, N = 5; TP2, nonsurvivors, N = 5.
Concluding remarks

Based on our findings, we believe that MDSCs might play a dual role in the early and late response to septic shock. Initially, MDSCs might help to mitigate the systemic hyperinflammation observed in the early stages of sepsis, as seen in several in vivo murine models of sepsis, and in a cohort of patients affected by cystic fibrosis and bacterial infection [7, 8, 22]. However, subsequently, the high PMN-MDSCs frequencies described in our postsepsis cohort might account for the long-term morbidity and high mortality observed in sepsis survivors [15, 16]. Although this cohort did not include subjects previously enrolled in the earlier time points, our data suggest that targeting MDSCs in long-term sepsis survivors might improve overall survival and quality of life. For example, in cancer patients, treatment with all-trans-retinoic acid promoted the differentiation of MDSCs, reduced their numbers, and improved T-cell responses [23, 24]. However, further investigations on sepsis survivors are encouraged, for example, to assess the immunosuppressive functions of the described MDSC subsets.

Finally, we demonstrate that unsupervised metaclustering algorithms are able to quickly identify the expansion of target immune subsets in clinical settings, thus, showing high potential for future use in operator-free screenings and diagnostics. Moreover, these algorithms proved to be useful for the identification of unknown or noncanonical cell subsets, even when analyzing datasets obtained with limited flow cytometry panels.

Methods

Study participants

Twelve adult patients admitted to the intensive care unit (ICU) of the St. Anne’s University Hospital in Brno with early septic shock were prospectively enrolled into the “study cohort.” Patients with chronic immunosuppression or receiving antibiotic therapy for more than 2 days were not enrolled. Blood and plasma samples were obtained at two time points: within 12 h (TP1), and at 3 days (TP2) after ICU admission. Secondly, six patients who had been successfully treated for sepsis at our department were retrospectively enrolled at 6 to 26 months from their initial ICU admission into the “postsepsis cohort.” Finally, seven healthy individuals of comparable age and health status were recruited into the “control cohort.” Patients with acute infection in the last 28 days or chronic immunosuppression were not enrolled in the study. Cohort details are summarized in Table 1.

Written informed consent was obtained from all enrolled patients. All procedures and protocols were approved by the institutional ethics committee (4G/2018).

Sample collection and preparation

All samples were processed within 2 h from collection. Blood was collected in BD Vacutainer® Tubes containing Sodium Hep-
responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 2010. 207: 1453–1464.
8 Rieber, N., Brand, A., Hector, A., Graepel-Mainka, U., Ost, M., Schafer, I., Wecker, I. et al., Flagellin induces myeloid-derived suppressor cell implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J. Immunol. 2013. 190: 1276–1284.
9 Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V. and Mandruzzato, S., Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin. Cytom. 2015. 88: 77–91.
10 Bronte, V., Brandau, S., Chen, S. H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S. et al., Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 2016. 7: 12150.
11 Rudd, K. E., Johnson, S. C., Ageas, K. M., Shackelford, K. A., Tsai, D., Klevlan, D. R., Colombaro, D. V. et al., Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020. 395: 200–211.
12 Delano, M. J., Scumpia, P. O., Weinstein, J. S., Coco, D., Nagarai, S., Kelly-Scumpia, K. M., O’Malley, K. A. et al., MyD88-dependent expansion of an immature Gr-1−CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007. 204: 1463–1474.
13 Makarenkova, V. P., Bansal, V., Matta, B. M., Perez, L. A. and Ochoa, J. B., CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 2006. 176: 2085–2094.
14 Schrijver, I. T., Theroude, C. and Roger, T., Myeloid-derived suppressor cells in sepsis. Front. Immunol. 2019. 10: 327.
15 Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Moore, F. A. et al., Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit. Care Med. 2017. 45: 253–262.
16 Mathias, B., Delmas, A. L., Ozragat-Basianti, T., Vanzant, E. L., Szpila, B. E., Mohr, A. M., Moore, F. A. et al., Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann. Surg. 2017. 265: 827–834.
17 Janols, H., Bergenzelc, C., Allaoui, R., Larsson, A. M., Ryden, L., Bjorns- son, S., Janciauskienè, S. et al., A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in Gram-positive cases. J. Leukoc. Biol. 2014. 96: 685–693.
18 Gentile, L. F., Cuenca, A. G., Efron, P. A., Ang, D., Bihorac, A., McKinley, B. A., Moldawer, L. L. et al., Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J. Trauma Acute Care Surg. 2012. 72: 1491–1501.
19 Van Gassen, S., Callebaut, B., Van Helden, M. J., Lambrecht, B. N., Demeester, P., Dhaene, T. and Saeys, Y., FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015. 87: 636–645.
20 Vetikan, E. K., Koinis, F., Giolibusani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D. et al., A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J. Immunol. Res. 2014. 2014: 659294.
21 Veglia, F., Hashimoto, A., Dweep, H., Sansevierio, E., De Leo, A., Tycyanov, E., Kessenkov, A. et al., Analysis of classical neutrophils and polymophonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J. Exp. Med. 2021. 218: e20201803.
22 Derive, M., Bouazza, Y., Alauzet, C. and Gibot, S., Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med. 2012. 38: 1040–1049.
Abbreviations: e-MDSC: early-stage myeloid-derived suppressor cells · HD: healthy donors · ICU: intensive care unit · MDSCs: myeloid-derived suppressor cells · M-MDSC: monocytic myeloid-derived suppressor cells · PMN-MDSC: polymorphonuclear myeloid-derived suppressor cells

Full correspondence: Dr. Jan Fríč, Pekařská 53, Brno 656 91, Czech Republic
e-mail: jan.fric@fnusa.cz

Received: 18/12/2020
Revised: 24/2/2021
Accepted: 26/3/2021
Accepted article online: 31/3/2021